Lumito (LUMITO) Q2 2024 earnings summary

Executive summary

• SCIZYS, Lumito's first product, achieved CE marking in July 2024, enabling commercial launch for the research market.

• The company transitioned from product development to commercialization, focusing on market outreach and sales.

• Sanna Wallenborg was appointed as the new CEO, effective August 19, 2024, to lead the commercialization phase.

Financial highlights

• Q2 2024 net sales were 0 TSEK, unchanged from Q2 2023; H1 2024 net sales reached 17 TSEK.

• Q2 2024 net loss after tax was -8,132 TSEK (vs. -7,423 TSEK in Q2 2023); H1 2024 net loss after tax was -15,244 TSEK.

• Cash flow from operations after working capital changes was -9,067 TSEK in Q2 2024 and -16,247 TSEK in H1 2024.

• Cash and cash equivalents at June 30, 2024, were 32,326 TSEK, up from 29,199 TSEK a year earlier.

• Equity at period end was 107,447 TSEK, with a solidity of 80%.

Outlook and guidance

• With CE marking achieved, Lumito is set to begin sales and installations of SCIZYS, targeting research laboratories initially.

• Commercial focus shifts to market penetration, customer acquisition, and establishing research collaborations.